Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466275 | 1.00 | CYP2E1 (0.50) | CYP2E1CYP2A6FGFR1MAPK13MAOA | |
| SCHEMBL8037303 | 0.82 | CYP1A2 (0.53) | CYP2E1CYP2A6MAOAMAOBALDH1A1 | |
| SCHEMBL29569613 | 0.81 | FGFR1 (0.45) | FGFR1MAOAMAOBALDH1A1 | |
| SCHEMBL25343448 | 0.81 | FGFR1 (0.45) | FGFR1MAOAMAOBALDH1A1 | |
| SCHEMBL3562687 | 0.79 | CYP2E1 (0.54) | CYP2E1CYP2A6MAPK13MAOAMAOB | |
| SCHEMBL12146179 | 0.79 | KDM2B (0.55) | CYP2E1CYP2A6FGFR1MAPK13MAOA | |
| SCHEMBL27913803 | 0.78 | FGFR1 (0.45) | CYP2A6FGFR1ALDH1A1KDM2BPHF8 | |
| SCHEMBL29935829 | 0.76 | FGFR1 (0.51) | CYP2A6FGFR1MAOAMAOBALDH1A1 | |
| SCHEMBL9451324 | 0.76 | CYP2E1 (0.54) | CYP2E1CYP2A6FGFR1MAPK13MAOA | |
| SCHEMBL6803732 | 0.76 | NR2E1 (0.55) | CYP2E1CYP2A6MAPK13MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076662-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| CN-114195780-A | Carbonyl heterocyclic compound and application thereof | 上海医药集团股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114195806-A | Carbonyl heterocyclic compound and application thereof | 上海医药集团股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, ABCC1, UGT2B7 | CYP2E1 12/4885CYP2A6 28/4885FGFR1 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.